The Moderna stock forecast from Wall Street would have you think this stock is overbought.
But there is more to Moderna stock than COVID vaccines…
Profit Alerts
Biotech & Pharma Alerts
The One mRNA Vaccine Stock to Buy Today
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Pfizer, BioNTech, and Moderna investors enjoyed massive gains from late 2020 to early 2021 as the "vaccine stocks" exploded in value as their product was authorized.
Here's the thing, though – the profits aren't finished.
One company is set to experience another round of big gains over the next year or more.
Michael A. Robinson has the ticker…
How to Profit in a $29 Billion “New Biotech” Sector
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Back in the late 1960s and early 1970s, psychedelics drugs like LSD were still legal and could be researched.
But in 1968 when the federal government criminalized them, a lot of promising research stopped.
Now the spotlight is back on these drugs and the success they’ve shown in clinical trials for treating a range of mental health conditions.
This is not only great news for people suffering from these conditions, but also for savvy investors who’ll get in on the ground floor of a market that could be worth more than $29 billion by the end of the decade.
Here’s Shah with all the details….
Ocugen Stock Is Like Catching Lightning in a Bottle
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
To say that Ocugen stock has been hot this year would be one of the biggest understatements of the decade.
Ocugen Inc.
(NASDAQ: OCGN) has seen its stock price gain 592% so far this year and almost 4,000% over the past 52 weeks.
The stock has gone from $0.18 to as much as $18 this year.
But will the stock continue its hot streak?
This COVID-19 Vaccine Stock Has More Upside Than Pfizer or Moderna
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Developing effective vaccines against a deadly global pandemic is certainly bullish for a stock.
Indeed, Moderna and Pfizer shareholders have put away as much as 516% and 51% gains, respectively.
And when a lot of investors see this, they fear they’ve missed out.
Well, Michael’s here to assure you that you haven’t; not by a long shot.
And today, he’s got a vaccine stock you should put at the top of your “must-buy” list for the week ahead… .
Why to Avoid Surface Oncology Stock Despite ARK Buying
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
If you are not paying attention to ARK Investments, you probably should be.
ARK invests in what they believe are disruptive innovations.
These are technologies and discoveries capable of changing the world and making a fortune for their investors.
Recently, an ARK fund bought shares of Surface Oncology (NASDAQ: SURF), a clinical-stage biotechnology company.
Should we jump on the bandwagon with this potentially explosive stock? Sadly, the answer is probably not.
We'll show you exactly why, including how to find stocks actually worth your money…
Why the Dow Jones Could Quickly Hit 35,000
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The anticipation is palpable… and building fast. We've had three reports on extremely effective upcoming coronavirus vaccines, and each report practically blows the last one out of the water.
First we heard preliminary reports that Pfizer and BioNTech's revolutionary messenger RNA (mRNA) coronavirus vaccine was 90% effective. That was great… until yesterday morning, when the biotechs got back in touch to say the real figure was something closer to 95%. And in the middle, we've heard from Moderna, which is reporting its mRNA vaccine is 94.5% effective.
Every time, stocks have taken off like a shot at the news; vaccines have helped push the Dow back above its February 2020 highs.
Here's the thing… setting aside the six vaccines The New York Times reports are in limited use in China and Russia – about which there are many unanswered questions – there are at least nine more coronavirus vaccines deep in phase 3, large-scale efficacy trials.
And there are no less than 55 more candidates in earlier, phase 1 and 2 trials. Some of these vaccine candidates won't advance, but others almost certainly will – two have already.
That all this has happened in less than a year is an "Apollo moonshot"-like scientific achievement. But that's also a whole lot of concentrated upside potential that could flood the markets and push stocks to almost unthinkable highs.
So I asked Money Morning Chief Investment Strategist Shah Gilani what it all means for us investors…
How to Trade Pfizer Stock for a 290% Profit in a Month
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Pfizer's recent news that their COVID-19 vaccine is 90% effective sent the market (and Pfizer's stock) soaring.
And while those who had already invested in the stock have made a nice return, Tom's going to show you the quick and easy way to almost quadruple your money on it…
Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Not every biotech company is doing well in the search for an effective COVID-19 vaccine or treatment.
And the latest firm to struggle is Eli Lilly, whose antibody clinical trial was paused due to failure to show any real results.
So today, Andrew's going to show you a much more profitable move to make instead of chasing every vaccine "breakthrough" news…
This Biotech Has Delivered 1,000% in Profits So Far; Here’s What’s Next
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
One perfectly positioned biotech Don’s going to tell you about today is close to hitting the crucial $1 billion threshold.
It hasn’t happened yet, but when it does, they’ll have done it faster than the likes of Apple or Google.
And if you’re finding out about it now, you’re just in time because the setup looks very promising.
But you’ll have to act fast, and grab the shares before Wall Street finds out about it….
Start the conversation